甲磺酸伊马替尼治疗慢性粒细胞白血病的临床疗效评价

Clinical efficacy of imatinib mesylate in the treatment of chronic myeloid leukemia

目的研究并探讨甲磺酸伊马替尼治疗慢性粒细胞白血病的临床疗效。方法选取60例慢性粒细胞白血病患者作为研究对象,采取计算机随机数字分组法将患者随机分为对照组、观察组,每组30例,对照组采取常规化疗方案治疗,观察组在常规化疗基础上加用甲磺酸伊马替尼口服,比较两组的临床疗效、不良反应、免疫功能指标、生存质量评分。结果观察组的客观缓解率高于对照组(P<0.05)。观察组的不良反应发生率低于对照组(P<0.05)。治疗后,两组免疫功能指标均得到改善(P<0.05),其中,观察组的免疫功能指标优于对照组(P<0.05)。治疗后,两组生存质量评分均明显提高(P<0.05),而观察组高于对照组(P<0.05)。结论采用甲磺酸伊马替尼治疗慢性粒细胞白血病,不仅具有显著的临床疗效和安全性,还可有效改善其免疫功能,提高其生存质量。

Objective To study and explore the clinical efficacy of imatinib mesylate in the treatment of chronic myelocytic leukemia. Methods 60 cases of chronic myelogenous leukemia patients were selected as the research object, they were randomly divided into the control group and the observation groupbytaking the computer random number table method, 30 cases in each group, the control group received routine chemotherapy treatment, the observation group based on routine chemotherapy combined with imatinib mesylate orally, the clinical efficacy, adverse reactions, immune functionand score of life qualitywere comparedbetween the two groups. Results The objective remission rate in the observation group was higher than that in the control group（P〈0.05）. The incidence of adverse reactions in the observation group was lower than that in the control group（P〈0.05）. After treatment, the immune function indexes in the two groups were improved（P〈0.05）, and the immune function indexesin the observation group were better than those in the control group（P〈0.05）. After treatment, the scores of life qualityin the two groups were significantly increased（P〈0.05）, while the observation group was higher than the control group（P〈0.05）. Conclusion The use of imatinib mesylate in the treatment of chronic myelogenous leukemia has great clinical efficacy and safety, and it can also improve its immune function and improve its quality of life.